良性宫颈细胞学检查的绝经后女性高危型人乳头瘤病毒的患病率——一项基于人群的队列研究

Prevalence of High-risk HPV in Postmenopausal Women with Benign Cervical Cytology - A Population-based Cohort Study.

作者信息

Asciutto Katrin Christine, Forslund Ola, Borgfeldt Christer

机构信息

Department of Obstetrics and Gynecology at Skåne University Hospital, Lund, Sweden

Department of Medical Microbiology, Division of Laboratory Medicine at Skåne University Hospital, Lund, Sweden.

出版信息

Anticancer Res. 2018 Jul;38(7):4221-4228. doi: 10.21873/anticanres.12718.

DOI:10.21873/anticanres.12718

PMID:29970554

Abstract

AIM

To compare the clinical performance of human papillomavirus (HPV) mRNA and DNA assays in postmenopausal women.

MATERIALS AND METHODS

A total of 5,925 postmenopausal women were tested with cytology and the Luminex HPV DNA assay. High risk-HPV-positive women with benign cytology underwent a complimentary HPV mRNA assay (APTIMA). Both assays and the cytological testing were repeated after 12 months.

RESULTS

A total of 334 women were found to be high-risk HPV-positive; 272 out of these women met the inclusion criteria. At follow-up, 25 (9.2%) out of the 272 included women had cytological abnormalities. HPV mRNA assay at follow-up had a sensitivity of 84% (95% confidence interval=63.9-95.4%) and a specificity of 60.2% (95% confidence interval=53.7-66.3%; p=0.0003) to detect these lesions. Corresponding values for the HPV DNA assay were 88% (95% confidence interval=68.8-97.4%) and 43.5% (95% confidence interval=37.2-49.4%).

CONCLUSION

The HPV mRNA assay offers a comparable sensitivity but a higher specificity than the HPV DNA assay in detecting precancerous cervical lesions.

摘要

目的

比较人乳头瘤病毒（HPV）mRNA检测与DNA检测在绝经后女性中的临床性能。

材料与方法

共有5925名绝经后女性接受了细胞学检查和Luminex HPV DNA检测。细胞学检查为良性的高危HPV阳性女性接受了免费的HPV mRNA检测（APTIMA）。12个月后重复进行这两种检测和细胞学检查。

结果

共发现334名女性高危HPV呈阳性；其中272名女性符合纳入标准。随访时，272名纳入研究的女性中有25名（9.2%）出现细胞学异常。随访时HPV mRNA检测对这些病变的检测灵敏度为84%（95%置信区间=63.9-95.4%），特异度为60.2%（95%置信区间=53.7-66.3%；p=0.0003）。HPV DNA检测的相应值分别为88%（95%置信区间=68.8-97.4%）和43.5%（95%置信区间=37.2-49.4%）。